Recent 8-K filings for SLXNW

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 13, 2026 12:41 UTC other_material item 7.01item 9.01

  Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site

source · SLXNW on sec.gov